BMI View: Low incomes and limited government budgets in emerging markets generally preclude the
uptake of modern medicines for diseases such as cancer, despite strong underlying demand from patients
and prescribers. As economies in non-traditional markets such as Gabo ..."
BMI View: Oil production in the country is stagnating. Despite government efforts to increase revenues
from the mining sector, BMI predicts that a combination of faltering production and relatively subdued oil
prices will prevent government revenues from rising in the face of b ..."
BMI View: While geographic diversification and investment into the pharmaceutical and healthcare
sectors of emerging economies like Gabon may be a favourable strategy for any multinational
pharmaceutical company, it is vital that a company recognises both the rewards and the ri ..."
BMI View: Increased longevity in developed markets translates into an increased demand for care for the elderly, healthcare services and medicines. However, despite increased life expectancy, in emerging markets such as Gabon communicable diseases will remain a significant health ..."
BMI View: There are emerging downside risks to our Gabon pharmaceutical and healthcare expenditure forecasts. Economic expansion is stagnating, which could lead to political instability. The country's muchpraised universal healthcare system is undergoing reforms, and the infectio ..."
There are emerging downside risks to our Gabon pharmaceutical and healthcare expenditure forecasts. Economic expansion is stagnating, which could lead to political instability. The country's much-praised universal healthcare system is undergoing reforms, and the infectious diseas ..."
BMI View: The recent announcement that Gabon's National Drug Office budget for 2012 would be
almost doubled compared with 2011 will be welcomed by pharmaceutical companies. However, we note
that the absolute funding is still very low and the vast majority of expenditure will be ..."